Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
Johnson & Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis ...
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 ...
Medical Dialogues16h
Phase 3 study comparing Yesintek with Stelara in adult patients with chronic plaque psoriasis shows positive results: Biocon Biologics
Bengaluru: BioconBiologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd. has announced ...
HealthShots on MSN10h
Can matcha tea promote hair growth?
Enjoy having a cup of green tea every morning for its benefits like weight loss? Meet its close relative – matcha. Made from ...
I will die on this hill: The 4 best beef tallow products that saved my skin
My face has been through it. Acne that laughed in the face of prescriptions. Perioral dermatitis that made me look like I had ...
PipelineReview.com16h
Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
BRIDGEWATER, NJ, USA and BENGALURU, India I March 7, 2025 I Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and ...